



Studying the Effect of Probiotics on Liver Factors and Disease Recovery in People with Hepatitis (Review)

Dadkhoda Sofi ¹, Batool Heydari Sadegh ², Hamed Taheri ³, Hossein Pour Masoomi ⁴, Shima Mohammadkhani ², Mehdi Jahantigh ^{5,*}

¹ Assistant Professor of Internal Medicine, Department of Internal Medicine, School of Medicine, Amir al Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran

² Department of Emergency Medicine, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

³ Assistant professor of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences Infectious Diseases, AlilbneAbitaleb Hospital, Zahedan university of Medical Sciences, Zabol, Iran

⁴ Department of Infectious Diseases, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

⁵ Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran

*Corresponding Author: Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran. Email: jahantighm@gmail.com

Received: 22 September, 2025; Accepted: 22 September, 2025

Abstract

Context: There is a common connection between the liver and the intestine, which is the main factor in the health of both organs. The bacterial flora in the intestine plays a very important role in improving the functions of liver cells; any change in the number and type of these microorganisms causes significant disorders in the liver.

Methods: This study was conducted by searching for articles on various sites with keywords in Persian and English.

Results: The results of various studies showed that the use of combination treatments with probiotic bacteria can have good protective effects against liver diseases, including hepatitis. Preliminary studies and clinical trials have shown that probiotics can reduce liver damage and accelerate cell repair by reducing systemic inflammation, improving intestinal barrier function, and regulating the immune response. In various liver diseases such as nonalcoholic fatty liver disease and chronic hepatitis, the use of probiotics has had positive results. Liver biomarkers such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are sensitive and reliable indicators of liver cell damage, whose levels increase during inflammation and injury. A faster decrease in these enzymes can indicate a quicker recovery of liver damage. Therefore, examining the effect of probiotics on changes in these biomarkers and also determining the time required for enzymes to return to normal levels can more accurately determine the role of this intervention.

Conclusions: In addition to helping to better understand the mechanisms of action of probiotics, the results of this study can provide valuable guidance for physicians in choosing adjuvant treatments and improving the quality of life of people with this disease. Finally, this study can play an important role in the development of health and medical policies at the national level and serve as a basis for future research in the field of the use of probiotics in viral liver diseases of patients.

Keywords: Probiotics, Biomarkers, Liver, Hepatitis

1. Context

Various extrinsic and intrinsic factors cause the destruction of liver cells, ultimately leading to liver disease. One of the most important factors is the change in the amount of bacteria in the intestinal tract, which is a high-risk factor for diabetes and obesity (1). The large intestine is home to 300 to 500 different species of

microorganisms, and the digestive system is closely connected to the liver (2). Alcohol, viruses, drugs, and alcohol are the main causes of hepatitis. According to one study, 10^9 colony-forming units (CFU)/mL and 10^{12} CFU/mL of bacteria may be found in the ileum and terminal colon. The amount of gram-negative and anaerobic bacteria that predominate in the intestinal tract is 100 to 1000 times more than aerobic bacteria.

Copyright © 2025, Sofi et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Sofi D, Heydari Sadegh B, Taheri H, Pour Masoomi H, Mohammadkhani S, et al. Studying the Effect of Probiotics on Liver Factors and Disease Recovery in People with Hepatitis (Review). Gene Cell Tissue. 2025; 12 (3): e166536. <https://doi.org/10.5812/gct-166536>.

The most common bacteria are *Porphyromonas*, *Bifidobacterium*, *Lactobacillus*, *Clostridium*, and *Escherichia coli* (3). Studies have also shown that the population pattern of microorganisms is unique to each individual and differs from others (4). In healthy individuals, the provision of certain nutrients is one of the activities associated with intestinal microorganisms (5). Intestinal bacteria play an important role in strengthening immunity against the entry of pathogens from outside. Probiotics are live, beneficial microorganisms that, when consumed in sufficient amounts by humans or animals, can have beneficial effects on the host's health by affecting the body's microbial flora (6, 7). Probiotics can modulate the host's immune response and prevent and treat diseases such as lactose intolerance, urogenital infections, gastrointestinal infections, allergies, antibiotic side effects, oral health issues including gum disease and halitosis, various cancers, and inflammatory bowel disease. Probiotics play a variety of roles in the body's health, but their most important function is maintaining the health of the gastrointestinal tract (8). Probiotics can be sold in the form of capsules, powders, tablets, fortified yogurts, cheeses, and milk. These probiotics are safe, and no apparent side effects have been observed among thousands of people who have consumed these products. Dairy foods can be a good carrier for delivering probiotics and prebiotics to the body (9). These organisms are also abundant in legumes, soybeans, and asparagus (10).

The word probiotic is derived from the Greek words "pro" (for) and "biot" (life). It was first used by Stillwell and Lilly in 1965 to refer to substances secreted by microorganisms. Parker used the word probiotic in 1974 to refer to microorganisms that contribute to the intestinal microbial balance, and in 1989, Fuller defined probiotics and stated that probiotics, as dietary supplements, exert beneficial effects on the host, thereby improving the balance of intestinal microbial flora. In 2002, a comprehensive definition of probiotics was given by WHO and FAO based on the fact that probiotics are live microorganisms that, when administered in adequate amounts, confer a beneficial effect on the growth of their host. For this reason, it can be said that these compounds are the opposite of antibiotics. Given that there are beneficial and harmful bacteria in every person's body and that a balance between beneficial and harmful bacteria is maintained in the body of a healthy person, many factors such as the use of antibiotics, chemotherapy, radiotherapy, environmental toxins, consumption of chlorinated water, and genetic factors can disrupt this balance and cause the destruction of beneficial microbes and the

dominance of pathogenic microbes in the host body. Probiotic food products have attracted more attention than ever before due to their nutritional value in addition to their therapeutic and health-promoting effects (11, 12). Today, the benefits of using probiotics in controlling various diseases have been identified, but further research in this field seems necessary.

2. Methods

A systematic literature search was conducted in PubMed, Scopus, Embase, Cochrane, Web of Science, and Google Scholar databases based on keywords.

3. Results

Intestinal microorganisms affect digestion and host immunity. Intestinal microorganisms are closely related to the liver. In liver cirrhosis, beneficial microorganisms are reduced, and harmful microorganisms are increased (13-16). In a study investigating probiotic supplementation in liver cancer in men in southern China, a significant reduction in AFB-N7 concentrations was observed in the group receiving probiotics (17). In a study by Ma et al., oral treatment with probiotics significantly reduced NKT cells in insulin resistance and hepatic steatosis (18). Another study also showed a positive effect of probiotics in alcoholic steatohepatitis (19).

In another study, the effect of probiotics on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels was investigated. In the study by Segawa et al., alcoholic liver injury was assessed by measuring the activity of ALT and AST in serum, and alcoholic fatty liver was assessed by the content of triglyceride (TG) and total cholesterol in the liver. Oral administration of *L. brevis* significantly prevented the increase in serum ALT and AST levels as well as the content of TG and total cholesterol in the liver caused by ethanol consumption (20).

A study investigated the effects of chronic alcohol consumption on gut flora and the potential therapeutic role of probiotics in alcohol-induced liver damage. In this study, patients received *Bifidobacterium bifidum* and *Lactobacillus plantarum* 8PA3 for 5 days versus standard treatment alone (abstinence plus vitamins). Results showed that ALT, AST, and γ -glutamyl transpeptidase (GGT) were significantly increased in the alcoholic group compared to the healthy control group (21). In a study investigating the effect of probiotics on biomarkers of liver cell damage and recovery time in a population of children with acute hepatitis A, the results showed that the gut microbiota profile of

patients with cirrhosis was very different from that of healthy individuals. This was demonstrated by a significant reduction in α -diversity and a decrease in the abundance of SCFA-producing bacteria, including *Firmicutes*, *Coprococcus*, and *Clostridium* IV. Pathogenic bacteria such as *Gammaproteobacteria*, *Villonella*, and *Bacillus* were significantly enriched in patients with cirrhosis (22).

4. Discussion

In the study by Zhdanovich and Martynov, which investigated the effect of probiotics in the treatment of acute hepatitis, a significant increase in the total number of bifidobacteria was observed in the main group after treatment. Additionally, in the main group of patients with AVHA, a significant increase in the total number of *E. coli* bacteria was observed after treatment (23). In today's society, long-term alcohol consumption worldwide increases the number of patients at risk of alcohol-related liver diseases. Since the available drugs to reduce liver disorders have significant side effects, probiotics are widely recommended for reducing liver diseases (24).

In a study by Xiong et al., the clinical efficacy of probiotics in the treatment of alcoholic liver disease was investigated. Probiotics reduced the inflammatory response of the liver and improved liver function (25). In another study that examined the effects of two probiotics, *Lactacaseibacillus casei* Grx12 and *Limosilatobacillus fermentum* Grx07, on liver mechanisms, the results showed that the amount of liver damage was reduced in this group (26). In a study by Li et al., probiotics and antibodies inhibited inflammatory activity and resolved fatty liver disease (27).

4.1. Conclusions

The results showed that probiotics had a very positive effect on the treatment of liver disease and enzymes.

Footnotes

Authors' Contribution: Study concept and design: B. H. and D. S.; Analysis and interpretation of data: H. T. and H. P.; Drafting of the manuscript: S. M.; Critical revision of the manuscript for important intellectual content: M. J.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: All data analyzed are publicly available from the relevant study groups.

Funding/Support: This research was funded by Zabol University of Medical Sciences.

References

- Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. *J Hepatol*. 2003;**38**(5):681-7. [PubMed ID: 12713883]. [https://doi.org/10.1016/s0168-8278\(03\)00097-7](https://doi.org/10.1016/s0168-8278(03)00097-7).
- Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol*. 2007;**5**(7): e177. [PubMed ID: 17594176]. [PubMed Central ID: PMC1896187]. <https://doi.org/10.1371/journal.pbio.0050177>.
- Neish AS. Microbes in gastrointestinal health and disease. *Gastroenterology*. 2009;**136**(1):65-80. [PubMed ID: 19026645]. [PubMed Central ID: PMC2892787]. <https://doi.org/10.1053/j.gastro.2008.10.080>.
- Guarner F, Malagelada JR. Gut flora in health and disease. *Lancet*. 2003;**361**(9356):512-9. [PubMed ID: 12583961]. [https://doi.org/10.1016/S0140-6736\(03\)12489-0](https://doi.org/10.1016/S0140-6736(03)12489-0).
- O'Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. *Clin Gastroenterol Hepatol*. 2007;**5**(3):274-84. [PubMed ID: 17368226]. <https://doi.org/10.1016/j.cgh.2006.12.009>.
- Imani Fooladi AA, Mousavi SF, Seghatoleslami S, Yazdani S, Nourani MR. Toll-like receptors: role of inflammation and commensal bacteria. *Inflamm Allergy Drug Targets*. 2011;**10**(3):198-207. [PubMed ID: 21428911]. <https://doi.org/10.2174/187152811795564064>.
- Ghasempour M, Sefidgar AA, Gharekhani S, Shirkhani L, Moghadamnia AA. [Comparison of the Effect of Probiotic Yogurt-Drink Kefir, % 0.2 Chlorhexidine and % 0.2 Sodium Fluoride Mouthwashes on Streptococcus Mutans: An In vitro Study]. *J Babol Uni Med Sci*. 2013;**15**(6):12-8. FA. <https://doi.org/10.18869/acadpub.jbums.15.6.12>.
- Singh VP, Sharma J, Babu S, Singla A, Rizwanulla. Role of probiotics in health and disease: a review. *J Pak Med Assoc*. 2013;**63**(2):253-7. [PubMed ID: 23894906].
- Cruz AG, Antunes AE, Sousa ALO, Faria JA, Saad SM. Ice-cream as a probiotic food carrier. *Food Res Int*. 2009;**42**(9):1233-9. <https://doi.org/10.1016/j.foodres.2009.03.020>.
- Caglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with Bifidobacterium DN-173 010 on salivary mutans streptococci and lactobacilli in young adults. *Acta Odontol Scand*. 2005;**63**(6):317-20. [PubMed ID: 16512103]. <https://doi.org/10.1080/00016350510020070>.
- Farahbakhsh M, Hakimi H, Bahram Abadi R, Zolfaghari MR, Doraki N. [Isolation of Probiotic Lactobacilli from Traditional Yogurts Produced in Rural Areas of Rafsanjan and their Antimicrobial Effects, 20012]. *J Rafsanjan Uni Med Sci*. 2013;**12**(9):733-46. FA.
- Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. *Int J Mol Sci*. 2020;**21**(3). [PubMed ID: 32046317]. [PubMed Central ID: PMC7037652]. <https://doi.org/10.3390/ijms21031136>.
- Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. *Hepatology*. 2015;**62**(4):1260-71. [PubMed ID: 25820757]. [PubMed Central ID: PMC4587995]. <https://doi.org/10.1002/hep.27819>.
- Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with

- cirrhosis and its complications. *J Hepatol.* 2014;**60**(5):940-7. [PubMed ID: 24374295]. [PubMed Central ID: PMC3995845]. <https://doi.org/10.1016/j.jhep.2013.12.019>.
15. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology.* 2011;**54**(2):562-72. [PubMed ID: 21574172]. <https://doi.org/10.1002/hep.24423>.
 16. Stojanov S, Berlec A, Strukelj B. The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease. *Microorganisms.* 2020;**8**(11). [PubMed ID: 33139627]. [PubMed Central ID: PMC7692443]. <https://doi.org/10.3390/microorganisms8111715>.
 17. El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. *Am J Clin Nutr.* 2006;**83**(5):1199-203. [PubMed ID: 16685066]. <https://doi.org/10.1093/ajcn/83.5.1199>.
 18. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. *J Hepatol.* 2008;**49**(5):821-30. [PubMed ID: 18674841]. [PubMed Central ID: PMC2588670]. <https://doi.org/10.1016/j.jhep.2008.05.025>.
 19. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. *Alcohol Clin Exp Res.* 2009;**33**(10):1836-46. [PubMed ID: 19645728]. [PubMed Central ID: PMC3684271]. <https://doi.org/10.1111/j.1530-0277.2009.01022.x>.
 20. Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed *Lactobacillus brevis* SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. *Int J Food Microbiol.* 2008;**128**(2):371-7. [PubMed ID: 18976829]. <https://doi.org/10.1016/j.ijfoodmicro.2008.09.023>.
 21. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. *Alcohol.* 2008;**42**(8):675-82. [PubMed ID: 19038698]. [PubMed Central ID: PMC2630703]. <https://doi.org/10.1016/j.alcohol.2008.08.006>.
 22. Wu Z, Zhou H, Liu D, Deng F. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis. *Front Cell Infect Microbiol.* 2023;**13**:1218552. [PubMed ID: 37483387]. [PubMed Central ID: PMC10361729]. <https://doi.org/10.3389/fcimb.2023.1218552>.
 23. Zhdanovich LG, Martynov VA. Probiotics and hepatoprotectors in the treatment of acute viral hepatitis. *Experim Clin Gastroenterol.* 2023; (10):8-13. <https://doi.org/10.31146/1682-8658-ecg-206-10-8-13>.
 24. Mishra G, Singh P, Molla M, Yimer YS, Dinda SC, Chandra P, et al. Harnessing the potential of probiotics in the treatment of alcoholic liver disorders. *Front Pharmacol.* 2023;**14**:1212742. [PubMed ID: 37361234]. [PubMed Central ID: PMC10287977]. <https://doi.org/10.3389/fphar.2023.1212742>.
 25. Xiong SY, Wu GS, Li C, Ma W, Luo HR. Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis. *Front Cell Infect Microbiol.* 2024;**14**:1358063. [PubMed ID: 38533380]. [PubMed Central ID: PMC10964906]. <https://doi.org/10.3389/fcimb.2024.1358063>.
 26. Sang J, Qu H, Liu D, Wa Y, Chen D, Chen X, et al. Beneficial Effects of Probiotics on Liver Injury Caused by Chronic Alcohol Consumption. *Fermentation.* 2024;**10**(3). <https://doi.org/10.3390/fermentation10030127>.
 27. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology.* 2003;**37**(2):343-50. [PubMed ID: 12540784]. <https://doi.org/10.1053/jhep.2003.50048>.